What is Lucigen?
Headquartered in Middleton, Wisconsin, Lucigen operates at the intersection of innovation and laboratory efficiency. The company specializes in the development of advanced molecular biology products designed to address complex challenges in DNA cloning, amplification, and protein expression. By streamlining workflows for next generation sequencing, Lucigen provides essential tools that empower researchers to overcome technical bottlenecks. Their market position is defined by a commitment to simplifying genomic research, offering a comprehensive suite of competent cells, enzymes, and specialized kits that serve as the backbone for high-throughput experimental environments.
How much funding has Lucigen raised?
Lucigen has raised a total of $3.9M across 2 funding rounds:
Private Equity
$1.7M
Angel/Seed
$2.2M
Private Equity (2012): $1.7M, investors not publicly disclosed
Angel/Seed (2014): $2.2M, investors not publicly disclosed
Key Investors in Lucigen
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Lucigen?
With the recent influx of capital, Lucigen is well-positioned to accelerate its research and development initiatives, focusing on the next generation of genomic tools. The strategic deployment of these funds will likely prioritize the expansion of their product portfolio to meet the increasing demand for high-fidelity sequencing solutions. As the life sciences industry shifts toward more integrated and automated laboratory processes, Lucigen's focus on simplifying complex molecular workflows provides a distinct competitive advantage. Future growth will likely involve scaling manufacturing capabilities to support global distribution and deepening their footprint in the rapidly evolving biotechnology landscape.
See full Lucigen company page
